DALLAS, March 20, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Ademola Daramola, D.Sc., has joined the company as Vice President, Quality and Compliance. Dr. Daramola has more than two decades of experience developing processes and managing workflows for a wide range of quality assurance, compliance and operational excellence in human drugs, vaccines and medical devices.
“Ademola is an accomplished leader in quality assurance and compliance across different functions, with deep experience in the pharmaceutical industry, including with the FDA,” said Sulagna Bhattacharya, co-founder and CEO of Nanoscope. “His expertise will be invaluable as we advance toward commercialization of our optogenetic therapies.”
Dr. Daramola has an extensive background in leading cross-functional teams, developing processes, and managing workflows for a wide range of quality assurance and compliance programs in the pharmaceutical and medical device industries. Most recently, he served as GMP Compliance Leader for the Bill & Melinda Gates Medical Research Institute, where he was responsible for ensuring that Gates MRI biologics, vaccines, and small molecules, manufactured at third-party sites, complied with requisite quality and safety regulations. Prior to that, he was Vice President and Global Head of Quality and Compliance for CIPLA. Dr. Daramola spent nearly eight years with the FDA as an International Relations Specialist and a Consumer Safety Officer for Drug and Medical Devices. He began his career as a chemist with Teva Pharmaceuticals. Dr. Daramola earned his doctorate and master’s degrees in Global Health from Nova Southeastern University. He has a Bachelor of Technology from Barry University, as well as a Bachelor of Science from Ondo State University in Nigeria.
“Nanoscope is at an important inflection point both in its growth as a company and with its lead candidate, MCO-010,” said Dr. Daramola. “I’m excited to work with this dynamic and talented team and I look forward to ensuring the highest standards of quality and compliance as we bring these life-changing therapies to patients.”
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
SOURCE Nanoscope Therapeutics